Ascentage Pharma Group International revenue

Ascentage Pharma Group International's revenue was $79.9m in fiscal 2025, down 41.4% on the year before. Since fiscal 2022 ($31.2m) it has grown at a compound 36.8% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascentage Pharma Group International: revenue history, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	31	31	136	80
Growth on the year before	—	+0.5%	+334.5%	−41.4%
Gross profit	28	27	132	73
Gross margin	89.5%	86.2%	97.0%	91.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Ascentage Pharma Group International	$79.9m	-41.4%	—
ADC Therapeutics SA	$79.6m	3.0%	—
Protalix Biotherapeutics, Inc.	$80.6m	30.1%	6.1%
Bicycle Therapeutics PLC	$83.5m	194.7%	49.8%
Assembly Biosciences, Inc.	$74.8m	125.1%	-3.3%
Verastem, Inc.	$87.5m	26.4%	58.4%

Compare with peers

Head to head: AAPG vs ADCT AAPG vs PLX AAPG vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascentage Pharma Group International's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascentage Pharma Group International.